T
Teresa L. Parsons
Researcher at Johns Hopkins University School of Medicine
Publications - 47
Citations - 1491
Teresa L. Parsons is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Nevirapine & Lopinavir. The author has an hindex of 19, co-authored 45 publications receiving 1366 citations. Previous affiliations of Teresa L. Parsons include Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Intermittent HIV-1 Viremia (Blips) and Drug Resistance in Patients Receiving HAART
Richard E. Nettles,Tara L. Kieffer,Tara L. Kieffer,Patty Kwon,Daphne Monie,Yefei Han,Teresa L. Parsons,Joseph Cofrancesco,Joel E. Gallant,Thomas C. Quinn,Thomas C. Quinn,Brooks Jackson,Charles Flexner,Kathryn A. Carson,Stuart C. Ray,Deborah Persaud,Robert F. Siliciano,Robert F. Siliciano +17 more
TL;DR: Most blips in this population appear to represent random biological and statistical variation around mean HIV-1 levels below 50 copies/mL rather than clinically significant elevations in viremia.
Journal ArticleDOI
Hyperosmolar sexual lubricant causes epithelial damage in the distal colon: potential implication for HIV transmission
Edward J. Fuchs,Linda A. Lee,Michael Torbenson,Teresa L. Parsons,Rahul P. Bakshi,Anita Guidos,Richard L. Wahl,Craig W. Hendrix +7 more
TL;DR: Because denudation plausibly increases the risk of HIV transmission, hyperosmolar gels make poor rectal microbicide formulations, and hyperOSmolar sexual lubricants may increase susceptibility to HIV infection, this evaluation evaluated the effects of hyperosmite gels on the rectal mucosa.
Journal ArticleDOI
Marked Intraindividual Variability in Antiretroviral Concentrations May Limit the Utility of Therapeutic Drug Monitoring
Richard E. Nettles,Tara L. Kieffer,Teresa L. Parsons,James E. Johnson,Joseph Cofrancesco,Joel E. Gallant,Kathryn A. Carson,Robert F. Siliciano,Robert F. Siliciano,Charles Flexner +9 more
TL;DR: Intraindividual variability in concentrations of antiretrovirals was surprisingly high in virologically suppressed patients, which may limit the utility of single measurements in therapeutic drug monitoring for some antireTroviral agents.
Journal ArticleDOI
Undisclosed Antiretroviral Drug Use in a Multinational Clinical Trial (HIV Prevention Trials Network 052)
Jessica M. Fogel,Lei Wang,Teresa L. Parsons,San San Ou,Estelle Piwowar-Manning,Ying Q. Chen,Victor Mudhune,Mina C. Hosseinipour,Johnstone Kumwenda,James Hakim,Suwat Chariyalertsak,Ravindre Panchia,Ian Sanne,Nagalingeswaran Kumarasamy,Beatriz Grinsztejn,Joseph Makhema,José Henrique Pilotto,Breno Santos,Kenneth H. Mayer,Marybeth McCauley,Theresa Gamble,Namandjé N. Bumpus,Craig W. Hendrix,Myron S. Cohen,Susan H. Eshleman +24 more
TL;DR: ARS drugs were detected in follow-up samples from participants who were not receiving study-administered treatment and may be useful in addition to self-report of ARV drug use in some clinical trial settings.
Journal ArticleDOI
Pharmacokinetics and Safety of Tenofovir in HIV-Infected Women During Labor and Their Infants During the First Week of Life
Mark Mirochnick,Taha E. Taha,Regis Kreitchmann,Karin Nielsen-Saines,Newton Kumwenda,Esau Joao,Jorge Pinto,Breno Santos,Teresa L. Parsons,Brian P. Kearney,Lynda Emel,Casey M. Herron,Paul G. Richardson,Sarah E. Hudelson,Susan H. Eshleman,Kathleen George,Kathleen George,Mary Glenn Fowler,Paul Sato,Paul Sato,Lynne M. Mofenson,Lynne M. Mofenson +21 more
TL;DR: A TDF dosing regimen of 600 mg during labor and daily infant doses of 6 mg/kg maintains infant tenofovir plasma concentration above 50 ng/mL throughout the first week of life and should be used in the studies of TDF efficacy for HIV prevention of mother-to-child transmission and early infant treatment.